

# Satu Mustjoki

List of Publications by Year  
in descending order

Source: <https://exaly.com/author-pdf/2785862/publications.pdf>

Version: 2024-02-01

305  
papers

11,642  
citations

31976  
53  
h-index

34986  
98  
g-index

324  
all docs

324  
docs citations

324  
times ranked

13707  
citing authors

#	ARTICLE	IF	CITATIONS
1	Somatic <math>\text{STAT3}</math> mutations in CD8<sup>+</sup> T cells of healthy blood donors carrying human T-cell leukemia virus type 2. Haematologica, 2022, 107, 550-554.	3.5	11
2	Structural and utational nalysis of ember-pecific STAT unctions. Biochimica Et Biophysica Acta - General Subjects, 2022, 1866, 130058.	2.4	3
3	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discovery, 2022, 12, 388-401.	9.4	73
4	T and NK cell abundance defines two distinct subgroups of renal cell carcinoma. Oncoimmunology, 2022, 11, 1993042.	4.6	16
5	Identification of novel STAT5B mutations and characterization of TCR<sup>Î²</sup> signatures in CD4+ T-cell large granular lymphocyte leukemia. Blood Cancer Journal, 2022, 12, 31.	6.2	15
6	Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia. HemaSphere, 2022, 6, e701.	2.7	4
7	JAK&#x2013;STAT core cancer pathway: An integrative cancer interactome analysis. Journal of Cellular and Molecular Medicine, 2022, 26, 2049-2062.	3.6	32
8	Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia. Nature Communications, 2022, 13, 1981.	12.8	23
9	Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation. Blood Cancer Journal, 2022, 12, 69.	6.2	10
10	Copy number alterations define outcome in Philadelphia chromosomepositive acute lymphoblastic leukemia. Haematologica, 2022, , .	3.5	1
11	Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. Haematologica, 2021, 106, 718-729.	3.5	75
12	RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia, 2021, 35, 1087-1099.	7.2	32
13	Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDS. Blood Cancer Discovery, 2021, 2, 238-249.	5.0	25
14	The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study. Leukemia and Lymphoma, 2021, 62, 2040-2043.	1.3	7
15	Predicting recognition between T cell receptors and epitopes with TCRGP. PLoS Computational Biology, 2021, 17, e1008814.	3.2	67
16	Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia. Leukemia, 2021, 35, 1365-1379.	7.2	41
17	Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis. Blood, 2021, 137, 2070-2084.	1.4	21
18	Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells. Blood Advances, 2021, 5, 1862-1875.	5.2	5

#	ARTICLE	IF	CITATIONS
19	Somatic Mutations in “Benign” Disease. New England Journal of Medicine, 2021, 384, 2039-2052.	27.0	111
20	Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia. Leukemia and Lymphoma, 2021, 62, 2064-2078.	1.3	15
21	Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. Journal of Medicinal Chemistry, 2021, 64, 8486-8509.	6.4	28
22	STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation. Leukemia, 2021, 35, 3430-3443.	7.2	20
23	Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma. Cancer Immunology Research, 2021, 9, 981-993.	3.4	22
24	Anti-“cytokine autoantibodies are rare in chronic graft-versus-host disease. Scandinavian Journal of Immunology, 2021, 94, e13091.	2.7	0
25	Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. Nature Genetics, 2021, 53, 1196-1206.	21.4	47
26	Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients. Modern Pathology, 2021, 34, 2229-2241.	5.5	25
27	Long-term tolerability and efficacy after initial PegIFN- $\alpha$ addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study. European Journal of Haematology, 2021, 107, 617-623.	2.2	4
28	Novel oncolytic adenovirus expressing enhanced cross-hybrid IgG A Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. , 2021, 9, e003000.		27
29	The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders. Blood, 2021, 138, 2781-2798.	1.4	27
30	Somatic STAT3 Mutations in CD8+ T Cells of HTLV-2 Positive Blood Donors. Blood, 2021, 138, 3133-3133.	1.4	0
31	FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study. Blood, 2021, 138, 633-633.	1.4	10
32	Functional Genomic Landscape of Natural Killer Cell Evasion in Multiple Myeloma. Blood, 2021, 138, 732-732.	1.4	1
33	Single-Cell Characterization of the Immune and Leukemic Cells Following Anti-TIM3 and Hypomethylating Agent Combination Therapy in Patients with AML or MDS. Blood, 2021, 138, 801-801.	1.4	0
34	Synergistic Role of Leukemic and Non-Leukemic Immune Repertoires in CD8+ T-Cell Large Granular Lymphocytic Leukemia As Identified By Single-Cell Transcriptomics. Blood, 2021, 138, 1318-1318.	1.4	1
35	OAB-019: CRISPR screens with single-cell transcriptome readout reveal potential mechanisms of response to natural killer cell treatment in multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S12-S13.	0.4	1
36	The Diverse Roles of $\gamma\delta$ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma. Cancers, 2021, 13, 6212.	3.7	13

#	ARTICLE	IF	CITATIONS
37	Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. <i>Haematologica</i> , 2020, 105, 1527-1538.	3.5	19
38	Modelling of killer T-cell and cancer cell subpopulation dynamics under immuno- and chemotherapies. <i>Journal of Theoretical Biology</i> , 2020, 488, 110136.	1.7	4
39	Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. <i>Leukemia</i> , 2020, 35, 1964-1975.	7.2	35
40	Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature. <i>Frontiers in Immunology</i> , 2020, 11, 578848.	4.8	11
41	CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia. <i>Biomarker Research</i> , 2020, 8, 54.	6.8	18
42	Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease. <i>Nature Communications</i> , 2020, 11, 2246.	12.8	20
43	STAT3 Mutation Is Associated with STAT3 Activation in CD30+ ALK <sup>-</sup> ALCL. <i>Cancers</i> , 2020, 12, 702.	3.7	17
44	Immunogenomic Landscape of Hematological Malignancies. <i>Cancer Cell</i> , 2020, 38, 380-399.e13.	16.8	109
45	Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML. <i>Cancer Research</i> , 2020, 80, 2394-2406.	0.9	30
46	Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine. <i>Leukemia</i> , 2020, 34, 2513-2518.	7.2	9
47	Somatic mutations and T-cell clonality in patients with immunodeficiency. <i>Haematologica</i> , 2020, 105, 2757-2768.	3.5	18
48	Novel Hemizygous IL2RG p.(Pro58Ser) Mutation Impairs IL-2 Receptor Complex Expression on Lymphocytes Causing X-Linked Combined Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2020, 40, 503-514.	3.8	11
49	Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 717-730.	4.2	18
50	Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy. <i>Leukemia Research</i> , 2020, 90, 106310.	0.8	6
51	Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma. <i>Cancers</i> , 2020, 12, 877.	3.7	32
52	A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells. <i>Blood Cancer Journal</i> , 2020, 10, 42.	6.2	22
53	Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. <i>Blood</i> , 2020, 135, 597-609.	1.4	134
54	Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. <i>Blood Advances</i> , 2020, 4, 274-286.	5.2	38

#	ARTICLE	IF	CITATIONS
55	Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. Blood Advances, 2020, 4, 546-559.	5.2	36
56	Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica, 2020, 105, 708-720.	3.5	99
57	Abstract LB-108: A potent and selective small molecule degrader of STAT5 for the treatment of hematological malignancies. , 2020, , .		4
58	Abstract 1115: Patient-derived explant cultures (PDECs) as a model system for immuno-oncology studies. , 2020, , .		0
59	Single-Cell Roadmap of Immune Cell Response in Chronic Myeloid Leukemia. Blood, 2020, 136, 4-5.	1.4	0
60	Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. Oncolimmunology, 2019, 8, e1638210.	4.6	19
61	Dominant TOM1 mutation associated with combined immunodeficiency and autoimmune disease. Npj Genomic Medicine, 2019, 4, 14.	3.8	11
62	CLINICAL SIGNIFICANCE OF T-CELL EXHAUSTION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Hematological Oncology, 2019, 37, 199-200.	1.7	0
63	Twins with different personalities: STAT5B“but not STAT5A”has a key role in BCR/ABL-induced leukemia. Leukemia, 2019, 33, 1583-1597.	7.2	40
64	Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia, 2019, 33, 1835-1850.	7.2	97
65	Characterization of polydactyly chondrocytes and their use in cartilage engineering. Scientific Reports, 2019, 9, 4275.	3.3	33
66	Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy. Nature Communications, 2019, 10, 620.	12.8	60
67	Subclonal STAT3 mutations solidify clonal dominance. Blood Advances, 2019, 3, 917-921.	5.2	28
68	Novel TMEM173 Mutation and the Role of Disease Modifying Alleles. Frontiers in Immunology, 2019, 10, 2770.	4.8	45
69	Therapy de-escalation before stopping in chronic myeloid leukaemia. Lancet Haematology,the, 2019, 6, e345-e346.	4.6	1
70	JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL. Cancers, 2019, 11, 1833.	3.7	38
71	A robust pipeline with high replication rate for detection of somatic variants in the adaptive immune system as a source of common genetic variation in autoimmune disease. Human Molecular Genetics, 2019, 28, 1369-1380.	2.9	16
72	Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL. Leukemia, 2019, 33, 1570-1582.	7.2	43

#	ARTICLE	IF	CITATIONS
73	T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. <i>Haematologica</i> , 2019, 104, 338-346.	3.5	38
74	BCR-ABL1 p190 in CML: A Minor Breakpoint with a Major Impact. <i>Blood</i> , 2019, 134, 190-190.	1.4	5
75	Abstract A065: Genome-scale CRISPR screens identify essential genes for tumor sensitivity to NK cells. , 2019, , .		0
76	Abstract A130: Metastatic melanoma patients responding to PD1 therapy have higher proportion of peripheral blood NKT-cells. <i>Cancer Immunology Research</i> , 2019, 7, A130-A130.	3.4	2
77	Abstract A085: High infiltration of NK cells expressing elevated LAG-3 in a subgroup of renal cell carcinoma patients. , 2019, , .		0
78	Abstract A134: Single-cell roadmap of the evolution of T-cell response during anti-LAG3 and anti-PD1 combination treatment in metastatic melanoma patients. , 2019, , .		0
79	PS973 BCL6 AS A PUTATIVE THERAPY TARGET IN ACUTE ERYTHROID LEUKEMIA. <i>HemaSphere</i> , 2019, 3, 438-439.	2.7	0
80	Abstract 980: Clinical impact of T-cell exhaustion in patients with diffuse large B-cell lymphoma. , 2019, , .		0
81	Abstract 458: Precision systems medicine in acute myeloid leukemia: real-time translation of tailored therapeutic opportunities arising from ex-vivo drug sensitivity testing and molecular profiling. , 2019, , .		0
82	CRISPR Screens Identify Mechanisms of Natural Killer Cell Evasion across Blood Cancers. <i>Blood</i> , 2019, 134, 3597-3597.	1.4	3
83	Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1647-1647.	1.4	3
84	Heterogeneity of Molecular Mechanisms Determining Blood Cancer Cell Lines Resistance to Natural Killer Cells in the Context of Tumor-Stromal Interactions: Insights from Studies of Pooled "DNA-Barcoded" Cell Line Panels. <i>Blood</i> , 2019, 134, 620-620.	1.4	0
85	T Cell Landscape of Immune Aplastic Anemia Reveals a Convergent Antigen-Specific Signature. <i>Blood</i> , 2019, 134, 108-108.	1.4	5
86	Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients. <i>Cancer Research</i> , 2018, 78, 2407-2418.	0.9	60
87	Aggressive natural killer-cell leukemia—mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. <i>Nature Communications</i> , 2018, 9, 1567.	12.8	107
88	Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. <i>Nature Communications</i> , 2018, 9, 697.	12.8	73
89	Sex bias in MHC I-associated shaping of the adaptive immune system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2168-2173.	7.1	51
90	ADA2 deficiency: Clonal lymphoproliferation in a subset of patients. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1534-1537.e8.	2.9	71

#	ARTICLE	IF	CITATIONS
91	Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-VI <sup>2</sup> + expansions. Scientific Reports, 2018, 8, 2534.	3.3	2
92	CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting. Haematologica, 2018, 103, 447-455.	3.5	39
93	Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncology, The, 2018, 19, 747-757.	10.7	444
94	O023â€...Rare seronegative destructive RA: identification of somatic mutations in the expanded CD8+ lymphocytes. , 2018, , .		0
95	Somatic <i>STAT3</i> mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia. Haematologica, 2018, 103, 304-312.	3.5	50
96	Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia, 2018, 32, 774-787.	7.2	75
97	Anti-PD1 therapy increases peripheral blood NKT cells and chemokines in metastatic melanoma patients. Annals of Oncology, 2018, 29, x3.	1.2	3
98	Immune cell phenotype and functional defects in Netherton syndrome. Orphanet Journal of Rare Diseases, 2018, 13, 213.	2.7	22
99	Non-Ph variants in CML: guilty drivers?. Blood, 2018, 132, 880-881.	1.4	1
100	Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia. Blood Advances, 2018, 2, 1572-1579.	5.2	24
101	PD-L1<sup>+</sup> tumor-associated macrophages and PD-1<sup>+</sup> tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma. Haematologica, 2018, 103, 1908-1914.	3.5	64
102	Clonal hematopoiesis in patients with rheumatoid arthritis. Blood Cancer Journal, 2018, 8, 69.	6.2	62
103	Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia, 2018, 32, 1643-1656.	7.2	75
104	Somatic Mutations in T Cells As Possible Regulators of Immunodeficiency. Blood, 2018, 132, 515-515.	1.4	1
105	RUNX1 Mutations Identify an Entity of Blast Phase Chronic Myeloid Leukemia (BP-CML) Patients with Distinct Phenotype, Transcriptional Profile and Drug Vulnerabilities. Blood, 2018, 132, 4257-4257.	1.4	6
106	Next-Generation Sequencing Reveals a T Cell Receptor Signature Characteristic of Patients with Aplastic Anemia. Blood, 2018, 132, 537-537.	1.4	2
107	Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types. Blood, 2018, 132, 264-264.	1.4	5
108	Abstract 3899: Discovery and clinical implementation of individualized therapies in acute myeloid leukemia based on ex vivo drug sensitivity testing and multi-omics profiling. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
109	Quantitative Multiplex Immunohistochemistry Identifies Immunosuppression in the AML Bone Marrow and NK-Cells As Prognostic Biomarker in Intermediate-Risk Patients. <i>Blood</i> , 2018, 132, 2774-2774.	1.4	0
110	Polyclonal Immune Response in T-LGL Leads to Clonal Expansions Preceding Occurrence of STAT3 Mutations Further Solidifying Clonal Dominance. <i>Blood</i> , 2018, 132, 516-516.	1.4	0
111	Genome-Scale CRISPR Screens Identify Essential Genes for Sensitivity to Natural Killer Cells in Hematological Malignancies. <i>Blood</i> , 2018, 132, 732-732.	1.4	0
112	Somatic Mutations in CD8+ T Cells in Patients with Chronic Immune Thrombocytopenia Are Associated with Increased Clonality and Cytotoxic Phenotype of CD8+ T Cells. <i>Blood</i> , 2018, 132, 131-131.	1.4	1
113	Immunogenomic Landscape of Hematological Malignancies. <i>Blood</i> , 2018, 132, 2596-2596.	1.4	1
114	Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo. <i>Blood</i> , 2018, 132, 3975-3975.	1.4	0
115	Health-Related Quality of Life Outcomes in Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Dasatinib and Low Dose Pegylated Interferon. <i>Blood</i> , 2018, 132, 4260-4260.	1.4	0
116	Somatic MED12 Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear Entry. <i>Human Mutation</i> , 2017, 38, 269-274.	2.5	20
117	Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models. <i>Cancer Immunology Research</i> , 2017, 5, 157-169.	3.4	36
118	Damaging heterozygous mutations in NFKB1 lead to diverse immunologic phenotypes. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 782-796.	2.9	113
119	Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. <i>Blood</i> , 2017, 129, 2384-2394.	1.4	113
120	Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach. <i>Leukemia</i> , 2017, 31, 1243-1246.	7.2	33
121	Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion. <i>Cytherapy</i> , 2017, 19, 689-702.	0.7	80
122	Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. <i>Nature Medicine</i> , 2017, 23, 692-702.	30.7	336
123	Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 175-184.	1.6	36
124	Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. <i>Haematologica</i> , 2017, 102, 1361-1367.	3.5	28
125	Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34+CD38 <sup>low</sup> stem and progenitor cells in chronic myeloid leukemia. <i>Biochemical and Biophysical Research Communications</i> , 2017, 490, 378-384.	2.1	11
126	Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis. <i>Nature Communications</i> , 2017, 8, 15869.	12.8	83



#	ARTICLE	IF	CITATIONS
127	Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1543-1554.	2.5	20
128	Combined immunodeficiency and hypoglycemia associated with mutations in hypoxia upregulated 1. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1391-1393.e11.	2.9	14
129	A novel class of somatic mutations in blood detected preferentially in CD8 + cells. <i>Clinical Immunology</i> , 2017, 175, 75-81.	3.2	35
130	Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner. <i>Clinical Cancer Research</i> , 2017, 23, 6697-6707.	7.0	41
131	NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib. <i>Leukemia</i> , 2017, 31, 2264-2267.	7.2	4
132	Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. <i>Leukemia</i> , 2017, 31, 1108-1116.	7.2	201
133	Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia. <i>PLoS ONE</i> , 2017, 12, e0171041.	2.5	7
134	Drug-perturbation-based stratification of blood cancer. <i>Journal of Clinical Investigation</i> , 2017, 128, 427-445.	8.2	124
135	Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. <i>Oncotarget</i> , 2017, 8, 22606-22615.	1.8	13
136	The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients. <i>Oncotarget</i> , 2017, 8, 34736-34749.	1.8	4
137	Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. <i>Oncotarget</i> , 2017, 8, 97516-97527.	1.8	28
138	Immune control in chronic myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 102763-102764.	1.8	9
139	Abstract 1372: Towards novel strategies of targeting specific vulnerabilities of T-PLL cells. , 2017, , .		0
140	High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. <i>Blood</i> , 2016, 128, 2465-2468.	1.4	86
141	IL1RAP antibodies block IL-1 $\alpha$ -induced expansion of candidate CML stem cells and mediate cell killing in xenograft models. <i>Blood</i> , 2016, 128, 2683-2693.	1.4	77
142	Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 4030-4038.	7.0	20
143	Safety and efficacy of the combination of pegylated interferon- $\beta$ and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. <i>Leukemia</i> , 2016, 30, 1853-1860.	7.2	60
144	Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia. <i>Leukemia</i> , 2016, 30, 1204-1208.	7.2	62

#	ARTICLE	IF	CITATIONS
145	Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli. <i>Leukemia Research</i> , 2016, 50, 95-103.	0.8	20
146	Somatic MED12 exon 1 nonsense mutation in T-cell acute lymphoblastic leukemia escapes nonsense-mediated mRNA decay and prevents protein nuclear localization. <i>European Journal of Cancer</i> , 2016, 61, S88.	2.8	0
147	Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. <i>Cancer</i> , 2016, 122, 1398-1407.	4.1	47
148	A6.02â€¦Somatic mutations in clonally expanded CD8 <sup>+</sup> T cells in patients with newly diagnosed rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A47.2-A48.	0.9	0
149	Intrafamily and Interfamilial Phenotype Variation and Immature Immunity in Patients With Netherton Syndrome and Finnish SPINK5 Founder Mutation. <i>JAMA Dermatology</i> , 2016, 152, 435.	4.1	36
150	Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1041-1050.	2.5	24
151	IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome. <i>Leukemia</i> , 2016, 30, 255-258.	7.2	38
152	A New Computational Method to Predict Long-Term Minimal Residual Disease and Molecular Relapse after TKI-Cessation in CML. <i>Blood</i> , 2016, 128, 3099-3099.	1.4	1
153	Molecular Characterization of Cytotoxic T Cell Repertoire in Aplastic Anemia and Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 3893-3893.	1.4	1
154	Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial. <i>Blood</i> , 2016, 128, 787-787.	1.4	43
155	No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial. <i>Blood</i> , 2016, 128, 789-789.	1.4	9
156	Abstract 1169: Somatic MED12 mutations in hematological malignancies. , 2016, , .		0
157	Abstract A115: Tyrosine kinase inhibitor therapy modulates immune checkpoints and TCR repertoire diversity in chronic myeloid leukemia. , 2016, , .		0
158	Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell Malignancies. <i>Blood</i> , 2016, 128, 2921-2921.	1.4	0
159	Indoleamine 2,3-Dioxygenase (IDO1) Levels and Activity Are Increased in Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) and Correlate with Molecular Response to Nilotinib Therapy. <i>Blood</i> , 2016, 128, 1912-1912.	1.4	0
160	Immune Cell Profiling in CML Bone Marrow By Multiplex Immunohistochemistry. <i>Blood</i> , 2016, 128, 1897-1897.	1.4	0
161	Immunological Monitoring of CML Patients during First-Line Bosutinib and Imatinib Treatment. <i>Blood</i> , 2016, 128, 3069-3069.	1.4	0
162	Telomere Length Shortening in the CML Leukemic Stem Cell Compartment Correlates with the Respective Clone Size: Evidence for Early Vs. Late Chronic Phase. <i>Blood</i> , 2016, 128, 4243-4243.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Dasatinib Exerts Differential Effects on Normal and BCR-ABL Positive Hematopoietic Cells in a Transgenic Mouse Model of Chronic Phase-CML. <i>Blood</i> , 2016, 128, 1885-1885.	1.4	0
164	Novel Mutations in Patients with Blast Crisis or Accelerated Phase Chronic Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1924-1924.	1.4	0
165	Pan-Hematopoietic Cancer Gene Expression Analysis Identifies Immunologically Active Acute Myeloid Leukemia Subtypes. <i>Blood</i> , 2016, 128, 1725-1725.	1.4	0
166	Subset-Specific Recurrence of Mutations and Identification of Functional Modules Provides New Clues about the Pathogenesis of Large Granular Lymphocyte Leukemia. <i>Blood</i> , 2016, 128, 4117-4117.	1.4	0
167	Early MRD-Negativity May Predict for Favorable Outcome Irrespective of Allogeneic Transplantation in TKI-Treated Patients with Ph-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 1598-1598.	1.4	0
168	Effects of Dasatinib and Interferon- $\gamma$ Combination Treatment on the Immune System in CML. <i>Blood</i> , 2016, 128, 627-627.	1.4	0
169	IL1RAP Antibodies Block IL1-Induced Expansion of Primitive CML Cells and Display Therapeutic Effects in Xenograft Models. <i>Blood</i> , 2016, 128, 1118-1118.	1.4	0
170	Novel Mutations in NOTCH and Altered Wnt/ $\beta$ -Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4103-4103.	1.4	1
171	CML Patients with Primary Resistance or Suboptimal Response to TKI Therapy Have Variants in Genes Affecting Drug Absorption and Metabolism. <i>Blood</i> , 2016, 128, 3071-3071.	1.4	2
172	Next-Generation Sequencing Analysis of Clonal Hierarchy and Dynamics in T-Large Granular Lymphocyte Leukemia Suggests Emergence of STAT3 Clones within Pre-Existing Dominant T-Cell Repertoire Responses Otherwise Silenced in Normal Individuals. <i>Blood</i> , 2016, 128, 2731-2731.	1.4	0
173	Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. <i>Blood</i> , 2015, 125, 639-648.	1.4	229
174	Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing. <i>Blood Cancer Journal</i> , 2015, 5, e309-e309.	6.2	19
175	Expression of immune checkpoint molecules in chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. <i>Annals of Oncology</i> , 2015, 26, viii5.	1.2	0
176	The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1181-1191.	4.1	71
177	Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). <i>Leukemia</i> , 2015, 29, 886-894.	7.2	92
178	The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. <i>Haematologica</i> , 2015, 100, 91-99.	3.5	88
179	Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase II study (<sc>N</sc>ord<sc>CML</sc>006). <i>European Journal of Haematology</i> , 2015, 94, 243-250.	2.2	61
180	Large Granular Lymphocyte Infiltration in the Bone Marrow in Children and Young Adults May Suggest Primary Immune Deficiency. <i>Blood</i> , 2015, 126, 1024-1024.	1.4	1

#	ARTICLE	IF	CITATIONS
181	Dominant NFKB1 Mutations Cause Antibody Deficiency and Autoinflammatory Episodes. Blood, 2015, 126, 206-206.	1.4	1
182	Mature, Adaptive-like CD56DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission. Blood, 2015, 126, 343-343.	1.4	3
183	Increased TACE (Tumor necrosis factor-alpha-converting enzyme; ADAM17) Activity Associates with Decreased CD62L Expression, Increased Soluble CD62L Plasma Levels and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP): Results from an ENEST1st Substudy. Blood, 2015, 126, 4033-4033.	1.4	1
184	Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients. Blood, 2015, 126, 477-477.	1.4	1
185	Abstract 4964: Nonsense MED12 mutation in a patient with T-cell acute lymphoblastic leukemia. , 2015, , .		0
186	Abstract 606: Novel somatic mutations in the DNA-binding and coiled-coil domain of the STAT3 gene in LGL-leukemia. , 2015, , .		0
187	Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study. Blood, 2015, 126, 4022-4022.	1.4	0
188	Low Expression of MiR-18a Distinguishes Pediatric and Adult Acute Lymphoblastic Leukemia from Each Other. Blood, 2015, 126, 4991-4991.	1.4	0
189	Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling. Blood, 2015, 126, 315-315.	1.4	0
190	Phenotypic and Functional Alterations of Bone Marrow Mesenchymal Stem and Progenitor Cells in Chronic Myeloid Leukemia. Blood, 2015, 126, 2398-2398.	1.4	0
191	Bone Marrow Lymphocytic Status during Tyrosine Kinase Inhibitor Therapy and Its Relation to Therapy Response in Chronic Phase Chronic Myeloid Leukemia Patients. Blood, 2015, 126, 4027-4027.	1.4	0
192	Exome Sequencing of Aggressive Natural Killer Cell Leukemia and Drug Profiling Highlight Candidate Driver Pathways in Malignant Natural Killer Cells. Blood, 2015, 126, 700-700.	1.4	0
193	Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN- $\gamma$ Monotherapy. PLoS ONE, 2014, 9, e87794.	2.5	41
194	Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon- $\gamma$ monotherapy. Leukemia and Lymphoma, 2014, 55, 934-937.	1.3	11
195	Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing. Experimental Dermatology, 2014, 23, 366-368.	2.9	12
196	Imatinib and pegylated IFN- $\gamma$ 2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response. European Journal of Haematology, 2014, 92, 413-420.	2.2	11
197	IFN- $\gamma$ induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia. Oncoimmunology, 2014, 3, e28781.	4.6	7
198	Dasatinib promotes Th1-type responses in granzyme B expressing T-cells. Oncoimmunology, 2014, 3, e28925.	4.6	38

#	ARTICLE	IF	CITATIONS
199	Spermidine/spermine N1-acetyltransferase activity associates with white blood cell count in myeloid leukemias. <i>Experimental Hematology</i> , 2014, 42, 574-580.	0.4	8
200	Terminal Deletion of 11q with Significant Late-Onset Combined Immune Deficiency. <i>Journal of Clinical Immunology</i> , 2014, 34, 114-118.	3.8	24
201	Immunology and Immunotherapy of Chronic Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 17-23.	2.3	24
202	826: Primary T-prolymphocytic leukemia (T-PLL) cells are sensitive to BCL-2 and HDAC inhibitors: Results from high-throughput ex vivo drug testing. <i>European Journal of Cancer</i> , 2014, 50, S200.	2.8	1
203	895: Dasatinib-induced reduction of tumor growth is accompanied by the changes in the immune profile in melanoma B16.OVA mouse model. <i>European Journal of Cancer</i> , 2014, 50, S219.	2.8	0
204	Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2014, 28, 1738-1742.	7.2	90
205	Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. <i>Nature Genetics</i> , 2014, 46, 812-814.	21.4	411
206	Uncovering the pathogenesis of large granular lymphocytic leukemia—novel STAT3 and STAT5b mutations. <i>Annals of Medicine</i> , 2014, 46, 114-122.	3.8	62
207	The use of multiplex platforms for absolute and relative protein quantification of clinical material. <i>EuPA Open Proteomics</i> , 2014, 3, 37-47.	2.5	30
208	Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study. <i>Blood</i> , 2014, 124, 151-151.	1.4	38
209	Reduced Expression of CD62L Is Associated with Increased ADAM17 Activity and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP). <i>Blood</i> , 2014, 124, 4522-4522.	1.4	1
210	Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells. <i>Blood</i> , 2014, 124, 812-812.	1.4	33
211	An open-label, phase 1b, dose-escalation study (CA180-373) of dasatinib plus nivolumab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS7119-TPS7119.	1.6	2
212	Abstract 2587: Dasatinib-induced reduction of tumor growth is accompanied by the changes in the immune profile in melanoma B16.OVA mouse model. , 2014, , .		0
213	Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling. <i>Blood</i> , 2014, 124, 917-917.	1.4	0
214	Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies. <i>Blood</i> , 2014, 124, 1771-1771.	1.4	0
215	Dasatinib-Induced Reduction of Tumor Growth Is Accompanied By the Changes in the Immune Profile in a Melanoma B16.OVA Mouse Model. <i>Blood</i> , 2014, 124, 1408-1408.	1.4	0
216	A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses. <i>Blood</i> , 2014, 124, 3139-3139.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes. <i>Blood</i> , 2013, 122, 4077-4085.	1.4	62
218	Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia. <i>Molecular Cytogenetics</i> , 2013, 6, 27.	0.9	28
219	Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. <i>Leukemia</i> , 2013, 27, 1520-1526.	7.2	60
220	Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2013, 3, 1416-1429.	9.4	334
221	Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. <i>Blood</i> , 2013, 121, 4541-4550.	1.4	252
222	Acute lymphoblastic leukemia associated with RCSD1â€“ABL1 novel fusion gene has a distinct gene expression profile from BCRâ€“ABL1 fusion. <i>Leukemia</i> , 2013, 27, 1422-1424.	7.2	8
223	Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. <i>Leukemia</i> , 2013, 27, 914-924.	7.2	84
224	Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. <i>Blood Cancer Journal</i> , 2013, 3, e168-e168.	6.2	56
225	STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. <i>Blood</i> , 2013, 122, 2453-2459.	1.4	128
226	Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia. <i>PLoS ONE</i> , 2013, 8, e55818.	2.5	102
227	The Association Of Dasatinib-Induced Lymphocytosis With Treatment Outcome In Patients With Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2013, 122, 2741-2741.	1.4	3
228	Disease Relapse After TKI Discontinuation In CML Is Related Both To Low Number and Impaired Function Of NK-Cells:Data From Euro-SKI. <i>Blood</i> , 2013, 122, 379-379.	1.4	12
229	Novel Activating STAT5B Mutations As Drivers Of T-ALL. <i>Blood</i> , 2013, 122, 3863-3863.	1.4	5
230	Dasatinib Treatment Induces Fast and Deep Responses In Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients In Chronic Phase: Clinical Results From a Randomized Phase 2 Study (NordCML006). <i>Blood</i> , 2013, 122, 4032-4032.	1.4	4
231	STAT5b in LGL leukemia - a novel therapeutic target?. <i>Oncotarget</i> , 2013, 4, 808-809.	1.8	6
232	Multiple STAT3 Mutations In Different Lymphocyte Clones Of Large Granular Lymphocytic Leukemia Patients. <i>Blood</i> , 2013, 122, 2559-2559.	1.4	0
233	Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing. <i>Blood</i> , 2013, 122, 3828-3828.	1.4	0
234	Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. <i>Blood</i> , 2013, 122, 482-482.	1.4	0



#	ARTICLE	IF	CITATIONS
235	High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1-Positive Leukemia. Blood, 2013, 122, 2719-2719.	1.4	0
236	Early PK-Analysis Predicts Molecular Response In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib. Blood, 2013, 122, 1485-1485.	1.4	0
237	Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib. Blood, 2013, 122, 2731-2731.	1.4	0
238	Leukemic Stem Cell Quantification Is Of Prognostic Value In Newly Diagnosed Patients In Chronic Phase Chronic Myeloid Leukemia (CML-CP) Receiving Nilotinib Therapy: Results From The ENEST1st Stem Cell Substudy. Blood, 2013, 122, 649-649.	1.4	0
239	Somatic <i>STAT3</i> Mutations in Large Granular Lymphocytic Leukemia. New England Journal of Medicine, 2012, 366, 1905-1913.	27.0	681
240	STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood, 2012, 120, 3048-3057.	1.4	360
241	758 Functional Characterization of NK- and T-cells in IFN- $\alpha$ Monotherapy Treated Chronic Myeloid Leukemia (CML) Patients. European Journal of Cancer, 2012, 48, S179-S180.	2.8	0
242	825 Exome Sequencing of T-LGL Leukemia Patient Revealed ANGPT2 as a Possible Mutational Target. European Journal of Cancer, 2012, 48, S198.	2.8	0
243	Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients. Experimental Hematology, 2012, 40, 705-714.e3.	0.4	16
244	Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia. Experimental Hematology, 2012, 40, 906-913.e1.	0.4	20
245	Morphology Antibody Chromosome Technique for Determining Phenotype and Genetic Status of the Same Cell. Current Protocols in Human Genetics, 2012, 74, Unit4.7.	3.5	0
246	Abstract 3175: Genomic and transcriptomic data integration in chronic myelomonocytic leukemia reveals a novel fusion gene involving onco-miR-125b-2. , 2012, , .		3
247	Abstract 5067: Exome sequencing reveals both DNA sequence and copy number changes in AML: Potential driver changes and mechanisms of drug resistance revealed from serial samples from the same patients. , 2012, , .		1
248	Discovery of STAT5b Mutations and Small Subclones of STAT3 Mutations in Large Granular Lymphocytic (LGL) Leukemia. Blood, 2012, 120, 871-871.	1.4	2
249	Abstract 895: Quantitative drug sensitivity and resistance testing (DSRT) of primary ex vivo AML blasts highlights mTOR and MEK as potential key molecular driver signals of therapeutic significance. , 2012, , .		0
250	Abstract 3188: Development of a cancer pharmacopeia-wide ex-vivo drug sensitivity and resistance testing (DSRT) platform for AML: Towards individually optimized therapy and improved understanding of drug resistance patterns. , 2012, , .		0
251	High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML. Blood, 2012, 120, 288-288.	1.4	1
252	Chronic Myeloid Leukemia Patients Undergoing Interferon Alpha Therapy Exhibit Normal Peripheral Blood Gamma Delta T Cells That May Be Expanded in Vitro to Generate Predominantly CD45RA-Positive Effector Memory Cells for Immunotherapy. Blood, 2012, 120, 3729-3729.	1.4	5

#	ARTICLE	IF	CITATIONS
253	Somatic PTPRT and ANGPT2 Mutations in Large Granulocyte Leukemia. <i>Blood</i> , 2012, 120, 1302-1302.	1.4	0
254	Functional Characterization of T- and NK-Cells in Chronic Myeloid Leukemia Patients Treated with Interferon- $\alpha$ Monotherapy.. <i>Blood</i> , 2012, 120, 2782-2782.	1.4	0
255	STAT3-Mutations Indicate the Presence of Subclinical Self-Reactive Cytotoxic T Cell Clones in Aplastic Anemia and Myelodysplastic Syndromes. <i>Blood</i> , 2012, 120, 646-646.	1.4	0
256	Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. <i>Leukemia</i> , 2011, 25, 1587-1597.	7.2	87
257	A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2011, 52, 668-679.	1.3	33
258	Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon- $\alpha$ Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile. <i>PLoS ONE</i> , 2011, 6, e23022.	2.5	44
259	Combination of pegylated IFN- $\alpha$ 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. <i>Blood</i> , 2011, 118, 3228-3235.	1.4	174
260	Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy. <i>Experimental Hematology</i> , 2011, 39, 102-113.e1.	0.4	15
261	Dasatinib Has a Dual Mode of Action: Direct BCR-ABL1 Mediated Anti-Leukemic Effects Are Complemented by Promotion of Th1-Type and NK-Cell Mediated Cellular Immune Responses,. <i>Blood</i> , 2011, 118, 3760-3760.	1.4	2
262	Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+ Progenitor Cell but Not At the CD34+CD38 $\alpha^+$ Stem Cell Level: Results From Randomized NordCML006 Study. <i>Blood</i> , 2011, 118, 784-784.	1.4	2
263	Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. <i>Blood</i> , 2011, 118, 2487-2487.	1.4	0
264	Tyrosine Kinase Inhibitor Therapy Induced Changes in Humoral Immunity in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2011, 118, 1699-1699.	1.4	4
265	Recurrent Missense Mutations in the STAT3 Gene in LGL Leukemia Provide Insights to Pathogenetic Mechanisms and Suggest Potential Diagnostic and Therapeutic Applications. <i>Blood</i> , 2011, 118, 936-936.	1.4	6
266	Phosphoprotein Profiling Predicts Response to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2011, 118, 4427-4427.	1.4	0
267	Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. <i>Blood</i> , 2010, 116, 772-782.	1.4	168
268	Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. <i>European Journal of Haematology</i> , 2010, 85, 387-398.	2.2	87
269	Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph+CD34+CD38neg) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy. <i>Leukemia</i> , 2010, 24, 219-222.	7.2	20
270	Interferon Alpha Treated Patients with Chronic Myeloid Leukemia (CML) In Prolonged Complete Remission Have Increased Numbers of NK-Cells and Clonal Gamma-Delta T-Cells, and a Distinct Plasma Cytokine Profile.. <i>Blood</i> , 2010, 116, 1201-1201.	1.4	4



#	ARTICLE	IF	CITATIONS
271	Dasatinib Induces a Rapid, Dose-Controllable Mobilization of Cytotoxic Lymphocytes: A Novel Immunomodulatory Effect Associated with Prolonged Therapy Responses In Advanced Leukemia.. Blood, 2010, 116, 1204-1204.	1.4	6
272	Occurrence, Management, and Outcomes In Patients with Pleural Effusion During Dasatinib Treatment for Chronic-Phase Chronic Myeloid Leukemia (CML-CP) In the First-Line Setting: Analysis of the DASISION Trial. Blood, 2010, 116, 2282-2282.	1.4	2
273	The Proportion of Ph+ CD34+CD38neg Leukemic Stem Cells in the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI-Therapy. Data From a Randomized Phase II NordCML006 Study. Blood, 2010, 116, 667-667.	1.4	0
274	Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms. Expert Review of Hematology, 2009, 2, 81-91.	2.2	3
275	Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosomeâ€‘positive acute lymphoblastic leukaemia. British Journal of Haematology, 2009, 145, 581-597.	2.5	53
276	Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia, 2009, 23, 1398-1405.	7.2	296
277	JAK2V617F mutation and spontaneous megakaryocytic or erythroid colony formation in patients with essential thrombocythaemia (ET) or polycythaemia vera (PV). Leukemia Research, 2009, 33, 54-59.	0.8	6
278	A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34). Haematologica, 2009, 94, 1469-1471.	3.5	34
279	Large Granular Lymphocyte (LGL) Expansions Comprising Oligoclonal T Cell or NK Cell Populations in Dasatinib Treated Patients Are Associated with HLA-A*0201, CMV Reactivation and Enhanced Anti-Leukemic Control.. Blood, 2009, 114, 1123-1123.	1.4	17
280	A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.. Blood, 2009, 114, 3280-3280.	1.4	2
281	Differential Effects of Imatinib and Dasatinib On Immune Effector Cells in Patients with Chronic Myeloid Leukemia (CML).. Blood, 2009, 114, 3285-3285.	1.4	10
282	Cytokine-Mediated Signaling Is Suppressed in Myeloid Cells and Enhanced in Lymphatic Cells in Patients with Chronic Myeloid Leukemia (CML) â€” Partial Normalization with Tyrosine Kinase Inhibitors.. Blood, 2009, 114, 2180-2180.	1.4	0
283	Mono/Oligoclonal T and NK Cells Are Common in Philadelphia Chromosome Positive (Ph+) Leukemia Patients at Diagnosis and Expand During Successful Tyrosine Kinase Inhibitor Therapy.. Blood, 2009, 114, 856-856.	1.4	1
284	Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosomeâ€‘positive leukemia. Blood, 2008, 112, 1005-1012.	1.4	366
285	Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia. Haematologica, 2008, 93, 178-185.	3.5	18
286	Oligoarray comparative genomic hybridization in polycythemia vera and essential thrombocythemia. Haematologica, 2008, 93, 1098-1100.	3.5	7
287	Imatinib Discontinuation Following a Major Molecular Response: Impact of Interferon Alpha and Leukemia Stem Cell Burden (The STOP Study).. Blood, 2008, 112, 2121-2121.	1.4	4
288	Low or Undetectable Numbers of Philadelphia Chromosome Positive (Ph+) Leukemia Cells in the Primitive (CD34posCD38neg) Stem Cell Fraction in Chronic Myeloid Leukemia (CML) Patients during Tyrosine Kinase Inhibitor Therapy.. Blood, 2008, 112, 1079-1079.	1.4	0

#	ARTICLE	IF	CITATIONS
289	Single-Cell Profiling of Aberrant Cytokine Signaling in Patients with Chronic Myeloid Leukemia (CML) at Diagnosis and during Dasatinib Therapy. <i>Blood</i> , 2008, 112, 4214-4214.	1.4	0
290	Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy. <i>Blood</i> , 2008, 112, 573-573.	1.4	3
291	Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia. <i>Leukemia</i> , 2007, 21, 2363-2368.	7.2	11
292	Clonal Large Granular Lymphocyte (LGL) Expansion Associated with Dasatinib Therapy.. <i>Blood</i> , 2007, 110, 2938-2938.	1.4	4
293	Appearance of Bone Marrow Lymphocytosis as a Sign of Immunoactivation Is Associated with a Good Response to Imatinib Therapy in Patients with Chronic Myeloid Leukemia.. <i>Blood</i> , 2006, 108, 4775-4775.	1.4	0
294	JAK2 Gene Is Mutated in Patients with Myeloproliferative Disorders and Spontaneous Erythroid Colony Formation but Not in Patients with Spontaneous Megakaryocyte Growth Only.. <i>Blood</i> , 2006, 108, 3600-3600.	1.4	1
295	VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. <i>Blood</i> , 2003, 101, 168-172.	1.4	356
296	Role of Plasminogen Activation in Hematopoietic Malignancies and in Normal Hematopoiesis. , 2003, , 217-235.		0
297	Intercellular adhesion molecule-1 in extravasation of normal mononuclear and leukaemia cells. <i>British Journal of Haematology</i> , 2001, 113, 989-1000.	2.5	15
298	Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. <i>EMBO Journal</i> , 2001, 20, 4762-4773.	7.8	705
299	Enhanced release of soluble urokinase receptor by endothelial cells in contact with peripheral blood cells. <i>FEBS Letters</i> , 2000, 486, 237-242.	2.8	30
300	Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. <i>Cancer Research</i> , 2000, 60, 7126-32.	0.9	75
301	Plasminogen activation in human leukemia and in normal hematopoietic cells. <i>Apmis</i> , 1999, 107, 144-149.	2.0	20
302	Blast Cell-surface and Plasma Soluble Urokinase Receptor in Acute Leukemia Patients: Relationship to Classification and Response to Therapy. <i>Thrombosis and Haemostasis</i> , 1999, 81, 705-710.	3.4	42
303	Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy. <i>Thrombosis and Haemostasis</i> , 1999, 81, 705-10.	3.4	11
304	Interferons and retinoids enhance and dexamethasone suppresses urokinase-mediated plasminogen activation in promyelocytic leukemia cells. <i>Leukemia</i> , 1998, 12, 164-174.	7.2	14
305	Plasma and cerebrospinal fluid activities of tissue plasminogen activator, urokinase and plasminogen activator inhibitor-1 in multiple sclerosis. <i>Fibrinolysis and Proteolysis</i> , 1997, 11, 109-113.	1.1	10